Evidence map›Paper›PMID 28138764›Full record

ReviewHerzschrittmachertherapie & Elektrophysiologie2017

[Ablation for atrial fibrillation in the elderly].

Clemens Jilek, Thorsten Lewalter

Abstract readReview
PubMed Publisher
In one paragraph

Review in Herzschrittmachertherapie & Elektrophysiologie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Clemens JilekPeter-Osypka-Herzzentrum München, Kliniken Dr. Müller München, Am Isarkanal 36, 81379, München, Deutschland. forschung@jilek.de.
Thorsten LewalterPeter-Osypka-Herzzentrum München, Kliniken Dr. Müller München, Am Isarkanal 36, 81379, München, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atrial fibrillation is mainly an arrhythmia among the elderly. The current ESC guideline determines that there is no justification to deny atrial fibrillation ablation to any age group; however, the guideline does not provide specific scientific data. Thus, the goal of this article is to summarize the data on efficacy and safety of atrial fibrillation ablation among elderly people and give treatment recommendations: (1) The success of atrial fibrillation ablation is the same between elderly and younger patients. (2) In cohort studies there was a trend to higher stroke rates among elderly people. (3) Negative predictors for stroke are an age >80 years, heart failure, stroke in history, or/and CHA

Indexed as

AgedAged, 80 and overAtrial FibrillationCatheter AblationCausalityComorbidityEvidence-Based MedicineFemaleHumansInternationalityMalePostoperative ComplicationsPrevalenceStrokeSurvival RateTreatment OutcomeAblationAtrial fibrillationEfficacyQuality of lifeStroke

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.